Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor-Targeted Agents


ANGELERGUES A., EFSTATHIOU E., GYFTAKI R., WYSOCKI P. J. , LAINEZ N., GONZALEZ I., ...Daha Fazla

CLINICAL GENITOURINARY CANCER, cilt.16, 2018 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 16 Konu: 4
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1016/j.clgc.2018.02.016
  • Dergi Adı: CLINICAL GENITOURINARY CANCER

Özet

Several agents have demonstrated an overall survival (OS) benefit in metastatic castration-resistant prostate cancer (mCRPC); however, optimal sequencing is unknown. Retrospective analysis of data from 574 mCRPC patients showed increasing OS with the number of therapies provided; a sequence including docetaxel, cabazitaxel (CABA), and an androgen receptor-targeted agent (ART) provided the greatest benefit. Prior administration of ART did not appear to influence CABA activity. These findings will help guide treatment decisions in daily practice.